The private equity firm and sovereign wealth fund took advantage of strong bond markets to raise funds to pay themselves a special dividend in an Indian outsourcing company.
MBK Partners has seen its sale of a 60% stake in CNS fall through again, underscoring the difficulty for private equity firms looking to exit Taiwan in the face of regulatory challenges.
MBK Partners will work with the National Pension Service to attract $2 billion capital for investments in Korea. Oaktree has allotted $3 billion for investments in Korea.
MBK Partners stands firm on its takeover offer which, as of April 30, had been accepted by 77.19% of AsiaPharmÆs shareholders. Templeton remains opposed to the deal.
The private equity company has no plans to raise its S$0.725 per share offer for the Chinese pharmaceutical firm, but reserves the right to revise the offer price if a competitive situation arises.
Templeton, a minority shareholder of AsiaPharm, is opposing a S$357.4 million management buyout offer for the Chinese pharmaceutical company and says the latest fourth quarter results are crucial in assessing the offer.